Présentation de l'entreprise
Galmed Pharmaceuticals Ltd. operates within the healthcare sector, specifically targeting the biotechnology industry with a specialized focus on therapeutic development for liver diseases. The company's primary business activity involves the research and development of Aramchol, which is characterized as a first-in-class synthetic fatty acid-bile acid conjugate molecule currently undergoing Phase III clinical trials for the oral treatment of non-alcoholic steatohepatitis. Regarding its financial scale, Galmed possesses a market capitalization of $4.11 million, while annual revenue and total employee count are not disclosed in the available data. The combination of a sub-$5 million market cap and the absence of reported revenue figures indicates that Galmed is a micro-cap entity operating in the early to mid-stage of its commercialization cycle, where capital allocation is predominantly directed toward clinical progression rather than established sales generation. This valuation tier suggests a high-risk, high-potential profile typical of biotechnology firms prioritizing asset development and regulatory approval over immediate profitability.
Santé financière
The financial statements reveal a net income of $-10,309,000 over the trailing twelve months, accompanied by an EBITDA of $-8,427,000, while revenue data is unavailable for the period. The significant divergence between the reported net income loss and the less severe EBITDA loss of $-8,427,000 highlights a cost structure where non-operating expenses or interest costs likely contribute substantially to the bottom-line deficit, a common characteristic in capital-intensive biopharma development. Free cash flow stands at $-4,374,125, which signifies a substantial cash outflow required to fund ongoing operations and clinical trials, thereby limiting immediate financial flexibility but being essential for advancing the Aramchol asset. The company reports three distinct margin metrics, all recorded at 0.0%: gross margin, operating margin, and profit margin. These zero percentages indicate that the company is not yet generating profit, a status expected for a firm still in the Phase III trial stage before commercial revenue scales. On the balance sheet, the company holds $18.16 million in cash against $0 in debt, resulting in a debt-to-equity ratio that is not applicable due to the absence of equity or debt figures in the provided data. This liquidity position, bolstered by $18.16 million in cash reserves, suggests a conservative approach to leverage with no outstanding debt obligations. Additionally, the current ratio is reported at 6.55, indicating a robust ability to meet short-term obligations with its liquid assets, providing a significant buffer against immediate liquidity pressures. Return on equity is -64.2% and return on assets is -28.7%, metrics that reflect the dilutive effect of losses on shareholder value and the efficiency of asset utilization during the development phase.
Évaluation de la valorisation
Valuation metrics for Galmed present a complex picture due to the lack of profitability, with a trailing P/E ratio listed as not applicable and a forward P/E of -0.60. The negative forward P/E of -0.60 implies that the market is pricing the stock based on expected future earnings that are currently negative, reflecting the high risk associated with the company's development stage. The price-to-book ratio is 0.18, suggesting that the market values the company at a fraction of its book value, which often occurs when intangible assets like clinical data and patent rights are significant but not fully captured on the balance sheet. Since price-to-sales data is not available, analysts must rely on the EV/EBITDA multiple of 1.67 as an alternative valuation metric, which remains low for a biotechnology firm, indicating a depressed valuation relative to traditional industry peers. The stock's price volatility is contextualized by a 52-week high of $2.68 and a 52-week low of $0.41. While the current trading price is not explicitly stated in the facts, the range of $2.27 defines the trading band within which the security has moved over the past year. The beta value is not applicable, which precludes a direct comparison of price volatility relative to the broader market index using this specific metric. These valuation figures collectively suggest a market perception that heavily discounts the company's current financial performance while waiting for potential commercialization milestones.
Growth & Income
Growth metrics for Galmed are not disclosed in the available facts, with revenue growth year-over-year and earnings growth year-over-year both listed as not applicable. The absence of historical growth data for revenue or earnings prevents a direct comparison between the speed of earnings growth and revenue growth, as the company has not yet achieved the scale necessary to calculate such rates. As a non-dividend payer, Galmed maintains a dividend yield of not applicable and a payout ratio of 0.0%, confirming that the company does not distribute cash to shareholders. This 0.0% payout ratio is consistent with the company's stage of development, where all available capital is reinvested into research, development, and clinical trials rather than being returned to investors. Consequently, the overall growth and income profile for Galmed Pharmaceuticals is defined entirely by its capital deployment in the Aramchol asset, with no current income stream to support shareholder returns or dividend payments.